Work

Clinical Use of CMV-Specific T Cells Derived From CMV-Naive Donors

Year: 2018

Type: article

Abstract: Background: Adoptive Immunotherapy with virus-specific T cells (VST) derived from hematopoietic stem cell (HSC) donors has been highly successful in preventing or treating CMV and other viruses in previous trials, but previously, VST could not be produced from adult virus-naïve donors. While “off the shelf” third party VSTs can offer a short term therapeutic approach for these patients, third party donor VSTs do not persist in these patients. Hence, we developed a novel approach to manufacture CMV-specific VST from CMV-naïve donors utilizing CD45RA selection and serial stimulation with virus peptide pulsed antigen presenting cells.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2017.12.041